Haynes and Boone represented Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, in a registered direct offering with certain healthcare-focused institutional investors for the sale of 20,000,000 shares of its common stock for gross proceeds of $40,000,000. H.C. Wainwright & Co. acted as the exclusive placement agent for the registered direct offering.
Representative Matters /
Pulmatrix Registered Direct Offering
Pulmatrix Registered Direct Offering
Related Practices
Participating Lawyers
![Fry Matt](/-/media/project/haynesboone/haynesboone/people/f/fry-matt/fry_matt_headshot.jpg?rev=473158ed2a4a44f299abc8c16da3d11d)
Partner | Co-Chair - Capital Markets and Securities Practice Group
T +1 214.651.5443 Email![Werner Rick](/-/media/project/haynesboone/haynesboone/people/w/werner-rick/werner_rick_headshot.jpg?rev=d61c187ccf544fecaaec7f46be23e4ff)
Partner | Co-Chair - Capital Markets and Securities Practice Group
T +1 212.659.4974 Email